An Exploratory Clinical Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Diseases
Latest Information Update: 23 May 2025
At a glance
- Drugs YTS 109 (Primary)
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Antiphospholipid syndrome; Antisynthetase syndrome; Dermatomyositis; Immune-mediated necrotising myopathy; Immunoglobulin G4-related disease; Lupus nephritis; Myositis; Polymyositis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma
- Focus Adverse reactions; Therapeutic Use
- Sponsors China Immunotech
Most Recent Events
- 23 May 2025 New trial record